NCT06396429

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Efficacy and Safety of HRS9531 in Overweight or Obese Participants: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 567 (actual)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.

Conditions

• Overweight or Obesity

Interventions

Type	Name	Description
DRUG	HRS9531 injection	HRS9531 injection; low dose
DRUG	HRS9531 injection	HRS9531 injection; medium dose
DRUG	HRS9531 injection	HRS9531 injection, high dose
DRUG	Placebo	blank preparation, participants received matching placebo.

Timeline

• Start date: 2024-05-13
• Primary completion: 2025-07-07
• Completion: 2025-07-07
• First posted: 2024-05-02
• Last updated: 2025-07-11

Locations

1 site across 1 country: China